DIRS.INFO The most relevant business & tech news

☆ FDA approves two new Abbott over-the-counter continuous glucose monitors
▼ + stars: | 2024-06-10 | by ( Ashley Capoot | In | ) www.cnbc.com time to read: +2 min

Abbott Laboratories announced Monday it received approval from the U.S. Food and Drug Administration for two new continuous glucose monitoring systems, including one for people who don't have diabetes. A continuous glucose monitor, or a CGM, is a small sensor that pokes through the skin and tracks a person's glucose levels in real time. One of Abbott's new systems, Libre Rio, is for patients with Type 2 diabetes who do not take insulin. Oftentimes, users need a valid CGM prescription to participate in these programs, so Abbott's new over-the-counter offering could be more accessible for some consumers. Abbott competitor Dexcom , which also sells CGM systems, received FDA approval for its first-ever over-the-counter CGM in March.

Persons: Robert B, Ford, Abbott, Abbot, Lingo, Dexcom Organizations: Abbott Laboratories, U.S . Food, Drug Administration, Libre Locations: Vegas, Las Vegas , Nevada, U.S, Libre Rio

☆ Facing an early death, a CEO created a 'digital twin' of his body. It transformed his health.
▼ + stars: | 2024-05-25 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +11 min

They can track a patient's health over time, suggesting personalized interventions. AdvertisementDonaldson was one of the first customers at Twin Health. Twin Health is the only company that leverages digital twin AI for diabetes "reversal" — or, as doctors prefer to say, "remission." If his blood sugar starts going up, he's noticed that getting out for a walk can help bring it back down. "All of my information goes in and it talks to me like a smarter version of myself saying, 'you ate this, this was really good.

Persons: —, Devlin Donaldson, he'd, that's, Donaldson, I'm, Omada, Twin's, Twin, he's, Nicola Guess, Guess, she's Organizations: Service, Business, Twin Health, Virta, Oxford University, Apple Watch, Twin Health Healthcare, McKinsey & Company

☆ Signos uses a glucose monitor patch and AI to help you eat healthier. Here's what it's like
▼ + stars: | 2024-03-09 | by ( Ashley Capoot | In | ) www.cnbc.com time to read: +13 min

SignosFounded in 2018, Signos uses continuous glucose monitors, or CGMs, and an artificial intelligence-powered app to help people better understand their metabolisms. But Signos' CGM system is meant for average consumers, so it is not intended for diabetes management. The Signos app walked me through the process step by step, offering a one-minute video and a series of GIFs I could watch. Another activity had me try and guess what I thought my glucose levels were at different points throughout the day. After eating a meal, I would often get a "Fast Rise" notification from my Signos app, which indicates that a glucose spike is occurring.

Persons: Ashley Capoot, I've, Signos, Dexcom, Sharam Fouladgar, you've, it's Organizations: CNBC, Abbott Laboratories, Centers for Disease Control, U.S . Food, Drug Administration, Dexcom Ventures, Bluetooth Locations: U.S, Mercer

☆ Dexcom announces its first-ever over-the-counter CGM Stelo has been cleared by the FDA
▼ + stars: | 2024-03-05 | by ( Ashley Capoot | In | ) www.cnbc.com time to read: +3 min

This means Stelo will be accessible to people who do not have insurance coverage for CGMs, Dexcom said. There are more than 25 million Type 2 diabetes patients in the U.S. that do not use insulin, according to the release from Dexcom. Dexcom shared Stelo's name, as well as the fact that the device had been submitted to the FDA for review in February. Jake Leach, chief operating officer at Dexcom, told CNBC in February that Stelo will have its own unique platform and branding. Leach said as Dexcom is able to demonstrate the benefits of Stelo, the company believes insurance companies will eventually pay for it.

Persons: Dexcom, it's, Dr, Jeff Shuren, Jake Leach, Stelo, It's, Leach Organizations: U.S . Food, Drug Administration, FDA's Center, Devices, Radiological, FDA, CNBC, CNBC PRO Locations: U.S

☆ As Ozempic and Wegovy take off, this tech startup just raised $20 million to tackle weight loss with data
▼ + stars: | 2023-10-24 | by ( Ashley Capoot | ) www.cnbc.com time to read: +6 min

Weight loss has always been big business, but it's exploded of late due to surging demand for Ozempic, Wegovy and other new diabetes and obesity drugs. "Whether you have five pounds to lose or 100, we want to make sure we're able to help everybody," Sharam Fouladgar-Mercer, Signos' co-founder and CEO, told CNBC in an interview. Fouladgar-Mercer said he created the company in 2018 partly because of his own struggle to manage weight throughout his life. Users can also integrate sleep data, heart rate data, and exercise data from their Apple Watch to personalize their profile even more. Fouladgar-Mercer said Signos can work well alongside Ozempic and Wegovy from Novo Nordisk and other GLP-1 treatments.

Persons: Signos, Mercer, it's, It's, GLP Organizations: Cheyenne Ventures, GV, Google Ventures, Dexcom Ventures, CNBC, Signos, U.S . Food, Drug Administration, Apple Watch, Abbott Laboratories, U.S, Novo Nordisk, Nordisk's Locations: Mercer, Novo, Europe, Fouladgar, America

How GLP-1 drugs work Sorting through the facts reveals some likely winners and losers. LLY YTD mountain Eli Lilly shares year to date performance It is still early days for GLP-1 medications. Many have seen the rise of GLP-1 drugs as a threat to the medical device industry. Also, not all patients are able to tolerate GLP-1 drugs, which can cause side effects such as nausea. Among other medtech stocks, Plovanic sees GLP-1 drugs as an "incremental positive" for Dexcom, which makes continuous glucose monitors (CGMs), but an "incremental negative" for insulin pump makers like Insulet.

Persons: Insulet, Medtronic, Dexcom, BAX, NASH, Eli Lilly, Peter Verdult, Lilly, Eli Lilly aren't, Piper Sandler, Wegovy, Yasmeen Rahimi, Robbie Marcus, Marcus, hasn't, Baxter, David Low doesn't, William Plovanic, Craig Wong, Pan, Plovanic, Matt O'Brien, O'Brien, Rippling, Simeon Gutman, Morgan Stanley, Gutman, — CNBC's Michael Bloom Organizations: Novo Nordisk, Baxter International, Baxter, GLP, Citi, Novo, Bank of America, Viking Therapeutics, Pharmaceuticals, Pfizer, Amgen, Companies, Fisher, Reuters, Inspire, Systems, JPMorgan, RBC Capital, Walmart, underperformance Locations: GLP, U.S, DaVita, ResMed

☆ Obesity drugs’ popularity put a dent in these stocks. Why analysts say they’re still worth buying
▼ + stars: | 2023-09-08 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +7 min

Industry analysts are insisting that new weight loss and diabetes drugs like Ozempic won't hurt the demand for insulin pumps and continuous glucose monitors, but most investors aren't buying it. The answer may depend on who you listen to and whether you see GLP-1 drugs as a help or a hinderance to the category. DXCM 3M mountain In the quarter to date, Dexcom shares are down nearly 19%. Dexcom shares are down more than 7% year to date. TNDM 3M mountain Tandem Diabetes shares have fallen significantly this year.

Persons: Ozempic, Danielle Antalffy, Eli Lilly's Mounjaro, hasn't, Dexcom, Piper Sandler, Matt O'Brien, O'Brien, Paresh Dandona, semaglutide, Travis Steed, Steed, — CNBC's Michael Bloom Organizations: UBS, Nordisk's, Novo, New, of Medicine, Tandem Diabetes, Tandem Diabetes Care, Diabetes, Jacobs School of Medicine, Biomedical Sciences, University of Buffalo, Novo Nordisk's, Bank of America Locations: CGMs

☆ A continuous glucose monitor helped me discover I have hypoglycemia. Here's how startup January uses AI to predict blood sugar spikes and crashes and coached me to better food choices.
▼ + stars: | 2023-08-14 | by ( Samantha Stokes | ) www.businessinsider.com time to read: +16 min

The healthcare startup January uses CGMs and AI to monitor glucose levels, exercise, and sleep. I have low blood sugar, and January used machine learning to coach me to healthier habits. Low blood sugar, or hypoglycemia, is less common than high blood sugar, or hyperglycemia. Samantha Stokes/InsiderAt the end of January's AI training, I unlocked a suite of tools to track my food, exercise, blood sugar, and more. But January encouraged me to take a short walk after eating, which can help moderate glucose levels following a meal.

Persons: Marc Benioff, they're, Noosheen Hashemi, Hashemi, Marissa Mayer, Samantha Stokes, Mike Snyder, Insider's, What's, I've, CGM, didn't, Jesus Weligsander Perez Organizations: Felicis Ventures, AME Cloud Ventures, Apple Watch, Drug Administration, Stanford Medicine, Pace Locations: That's, SignalFire, Mount Sinai

☆ As weight loss drug stocks rallied on a landmark study, these stocks were over sold, analysts say
▼ + stars: | 2023-08-11 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +8 min

However, the pharmaceutical companies are making the case that weight loss can improve health, and possibly lower health-care costs over time. But analysts have said the news isn't all bad for such stocks, and many were fell too low on Tuesday. Deutsche Bank analyst Imron Zafar estimated Thursday that bariatric surgery accounts for about 5% of Intuitive Surgical's U.S. robotic surgery business, but has been driving much of the company's growth. Some of the surgeons Zafar spoke with said any drop off in bariatric surgery was likely to be offset by increased use of the robot for other procedures. But they expect the drugs will remain necessary because GLP-1 drugs have yet to show they improve fibrosis, which is associated with NASH.

Persons: nonalcoholic steatohepatitis, NASH, Abbott, Robbie Marcus, Marcus, Marcus doesn't, Goldman Sachs, Goldman, Stryker, Smith, Zimmer Biomet, Bariatric, Imron Zafar, Zafar Organizations: Novo Nordisk, Abbott Laboratories, CNBC, JPMorgan, Companies, Inspire Medical Systems, Resmed, Philips, Nephew, Deutsche Bank, Madrigal Pharmaceuticals, Sagimet Biosciences, Akero Therapeutics, Terns Pharmaceuticals, Viking Therapeutics, Madrigal Locations: U.S

☆ New ETFs give income investors different ways to play volatile bond yields in the second half
▼ + stars: | 2023-07-07 | by ( Jesse Pound | In Jesse-Pound | ) www.cnbc.com time to read: +4 min

The Pimco Multisector Bond Active ETF (PYLD) launched in June, giving investors a way to follow one of the biggest names in fixed income during the volatile bond market. As the fixed income ETF market matures, major asset managers are trying their hand at multisector bond funds. Recent launches include Capital Group's U.S. Multisector Income ETF (CGMS) and BlackRock's Flexible Income ETF (BINC) , which is co-managed by Rick Rieder , the firm's chief investment officer for global fixed income. For financial advisors or investors who want to make investment decisions themselves, there are more targeted bond funds available. "There's a pretty long runway for investors to increase their allocation to fixed income.

Persons: Rick Rieder, Dan Ivascyn, Sonali Pier, D.J, Tierney, you've, Schwab, Schwab's Tierney Organizations: Treasury, Capital, Multisector, Pimco, CNBC, Schwab Asset Management, Fed Locations: Capital Group's, U.S, iShares

☆ Here's what's next for income ETFs after yields surged last year
▼ + stars: | 2023-02-16 | by ( Jesse Pound | ) www.cnbc.com time to read: +4 min

International income One area where investors may look next for income is the international market, which has outperformed the U.S. in the opening weeks of 2023. Both Amplify and Schwab offer international versions of their yield funds — Amplify International Enhanced Dividend Income ETF (IDVO) and Schwab International Dividend Equity ETF (SCHY). Fixed income funds Another area that could pay off for investors is fixed income. "This is a once in many, many year opportunity to de-risk, rebalance, get back into fixed income," said Stephen Laipply, US Head of iShares Fixed Income ETFs. The fixed income ETF market is much smaller than the equity ETF market, and 2023 could see a continued growth in new categories.

☆ Abbott has a new glucose monitor for diabetics — It's so small I forgot I was wearing it
▼ + stars: | 2022-10-14 | by ( Erin Black | ) www.cnbc.com time to read: +4 min

Continuous glucose monitors (CGMs) allow diabetics to track their blood sugar 24/7. They're incredibly useful, providing insight on how your blood sugar reacts to insulin, food, exercise and whatever else affects it. Abbott Freestyle Libre 3 sensor CNBC | Andrew EversThe trend arrows tell you if your glucose is steady, rising or falling. Abbott Freestyle Libre 3 size vs Dexcom G6 CNBC | Erin BlackIt was accurate most of the time. Abbott Freestyle Libre 3 Apple iWatch notification CNBC | Erin BlackPrescription required, price varies

Search resuls for: "CGMs"

12 mentions found